Clinical

Dataset Information

0

Phase I study of cetuximab plus U3-1565 in colorectal cancer with resistance to anti-EGFR antibody


ABSTRACT: Interventions: Level1 First dose Cetuximab: 400 mg/m2 div day1 U3-1565: 24 mg/kg div day1 From second dose on Cetuximab: 250 mg/m2 div. day1,8 U3-1565: 16 mg/kg div day1 q2w Level0 First dose Cetuximab: 400 mg/m2 div day1 U3-1565: 16 mg/kg div day1 From second dose on Cetuximab: 250 mg/m2 div day1,8 U3-1565: 12 mg/kg div day1,8 q2w Primary outcome(s): Proportion of DLT(Dose limiting toxicity) Study Design: Single arm Non-randomized

DISEASE(S): Colorectal Cancer

PROVIDER: 2628359 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2612965 | ecrin-mdr-crc
| 2625026 | ecrin-mdr-crc
| 2623074 | ecrin-mdr-crc
| 2626017 | ecrin-mdr-crc
2014-02-25 | GSE48126 | GEO
| phs001305 | dbGaP
| 2617576 | ecrin-mdr-crc
2016-07-31 | E-GEOD-75087 | biostudies-arrayexpress
| 2622442 | ecrin-mdr-crc
| 74818 | ecrin-mdr-crc